ADC Therapeutics SA (ADCT) Tops Q4 EPS by 47c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/27/2026

1. ORCL
2. AVGO
3. CDNS
4. ANT
5. SPY
6. META
7. BA
8. HOOD
9. INTC
10. JBLU

Go back to ADC Therapeutics SA (ADCT) Tops Q4 EPS by 47c

ADC Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates

March 3, 2022 7:00 AM EST

ZYNLONTA® (loncastuximab tesirine-lpyl) net sales of $17.0 million in the fourth quarter of 2021 and $33.9 million in FY 2021 following May launch

LOTIS-5 Phase 3 confirmatory trial of ZYNLONTA in combination with rituximab safety lead-in complete and now enrolling randomized portion of study

Company to host conference call today at 8:30 a.m. EST

LAUSANNE, Switzerland--(BUSINESS WIRE)-- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for... More